e-ISSN: Pending
Negative / Null Result ReportOpen accessImmunologic diseases. Allergy

Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study

Kenji Morimoto; Junji Uchino; Takashi Yokoi; Takashi Kijima; Yasuhiro Goto; Akira Nakao; Makoto Hibino; Takayuki Takeda · 2021 · OncoImmunology

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

Although previous studies suggest that cancer cachexia is a poor prognostic factor for immune checkpoint inhibitor monotherapy, the impact of cancer cachexia on chemoimmunotherapy is unclear. We investigated the impact of cancer cachexia on the therapeutic outcomes of chemoimmunotherapy for non-small cell lung cancer (NSCLC). We retrospectively analyzed patients’ medical records with NSCLC who received chemoimmunotherapy in 12 institutions in Japan between January and November 2019. We defined cancer cachexia as weight loss exceeding 5% of the total body weight or a body mass index of < 20 kg/

Abstract by Kenji Morimoto; Junji Uchino; Takashi Yokoi; Takashi Kijima; Yasuhiro Goto; Akira Nakao; Makoto Hibino; Takayuki Takeda, OncoImmunology (2021) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: DOAJ · DOI 10.1080/2162402x.2021.1950411